Marie Osdoit

Gynecologic surgeon, breast and gynecologic Oncology @institutcurie

[Paolo Tarantino @PTarantinoMD]

With #ASCO23-week officially here, it is time for a #top10 list of breast abstracts! Several potentially practice-changing trials to be presented during the congress. Take a look, share if you found it useful and feel free to recommend additional impactful abstracts to add! #bcsm

[Marie Osdoit @MarieOsdoit]

HER2 faible dans le #cancerdusein. HER2 comme un vecteur de chimiothérapie par l’effet bystander des nouvelles ànit-corps conjugués de 3ème génération. Merci pour votre présentation lors de la 24ème journée d’oncologie senologiaue et gynécologique du @CLCCLeonBerard

[Marie Osdoit @MarieOsdoit]

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial - PubMed https://t.co/X6qVhRw3ZQ

[Marie Osdoit @MarieOsdoit]

#ovariancancer Who should have maintenance bevacizumab? An aswer with the KELIM score
⁦@ArcagyGineco⁩ ⁦@GroupeUnicancer⁩ https://t.co/pNjh8zB4Hz

[Marie Osdoit @MarieOsdoit]

#breastcancer is not a simple disease but multiple of different one. Understanding that will allow us to give the best treatment
Low-Risk or Ultralow-Risk Breast Cancer? The Differences Are More Than Semantics https://t.co/ehXZVM5GCg

[Marie Osdoit @MarieOsdoit]

Next step in deescalation in #BreastCancer: no surgery after neoaduvant chemotherapy? Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial https://t.co/84oCgsUZ4M

[Marie Osdoit @MarieOsdoit]

521MO Efficacy of pembrolizumab monotherapy for advanced clear cell gynaecological cancer : Phase II PEACOCC trial - Annals of Oncology. A possible future area of treatment for clear cell gynecologic cancer?⁩ ⁦@ESGO_society⁩ ⁦@ArcagyGineco⁩ https://t.co/4huX0MKUCj

[Marie Osdoit @MarieOsdoit]

Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III Trial | Journal of Clinical Oncology https://t.co/JgZgjzAMtv

[Marie Osdoit @MarieOsdoit]

https://t.co/eygc4CcezW

[Marie Osdoit @MarieOsdoit]

Next step in #ovariancancer comprehension?
https://t.co/7RWnz7LPsh

[soria @jsoriamd]

A comprehensive transcriptional atlas of the cellular architecture of #breastcancer. Using single-cell signatures breast cancer cohorts were stratified into nine clusters with unique cellular compositions & clinical outcomes.
https://t.co/i11MZVfymH

[Marie Osdoit @MarieOsdoit]

Parlons #vaccination. Mieux que le dépistage, la #prevention... Vaccin contre l'HPV, prévenir le #cancer du col de l'utérus @GroupeUNICANCER @ESGO_society @myESMO @laliguecancer @reseauKgyneco
https://t.co/X7syySMgih
https://t.co/Xb8Fm1EyY7

[Marie Osdoit @MarieOsdoit]

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial https://t.co/niqpEexkod

[Marie Osdoit @MarieOsdoit]

@ISPY2trial Beautiful results and great graphes to remind us the power of RCB and how different are all #breastcancer!
https://t.co/IUvr6BsUvE

[Marie Osdoit @MarieOsdoit]

Timing is important. #breastcancer survival is related to the delay to complete the treatment
Important to remember it
https://t.co/tSeoxfn8oR

[Marie Osdoit @MarieOsdoit]

https://t.co/CRfuGxML7E

[Marie Osdoit @MarieOsdoit]

An intermediate solution to protect #BRCA patients against #OvarianCancer...
Waiting for the oncologie safety results!
https://t.co/GR2JnEC0mX

[Marie Osdoit @MarieOsdoit]

Neoadjuvant endocrine therapy can be a good treatment for selected patients with Luminal #breastcancer.
Let's follow that study!
https://t.co/wMcNqIsSJR

[Marie Osdoit @MarieOsdoit]

Go back to basics to improve our conclusions.
Thanks @stolaney1!
https://t.co/brzWbKTfDd

[Marie Osdoit @MarieOsdoit]

Secondary Cytoreduction and Carboplatin HIPC for Platinum-Sensitive Recurrent Ovarian CANCER
https://t.co/5W6ra2tkzj